About: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Creator	Zhang, Jing Zhong, Wu Chen, Li Liu, Lei Liu, Yingxia Peng, Ling Wang, Fuxiang Wang, Zhaoqin Yang, Yang Zhang, Zheng Chen, Jun Liao, Xuejiao Liu, Jiaye Cao, Ruiyuan Shen, Chenguang Yang, Minghui Cai, Qingxian Cai, Qiue Chen, Shuyan Gu, Yuanbo Huang, Deliang Li, Xiaohe Liu, Dongjing Shu, Dan Xia, Junxia Zhang, Shurong
Source	Elsevier; Medline; PMC
abstract	Abstract An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) has been reported in China since December 2019. More than 16% of patients developed acute respiratory distress syndrome, and the fatality ratio was about 1%–2%. No specific treatment has been reported. Herein, we examine the effects of Favipiravir (FPV) versus Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19. Patients with laboratory-confirmed COVID-19 who received oral FPV (Day 1: 1600 mg twice daily; Days 2–14: 600 mg twice daily) plus interferon (IFN)-α by aerosol inhalation (5 million U twice daily) were included in the FPV arm of this study, whereas patients who were treated with LPV/RTV (Days 1–14: 400 mg/100 mg twice daily) plus IFN-α by aerosol inhalation (5 million U twice daily) were included in the control arm. Changes in chest computed tomography (CT), viral clearance, and drug safety were compared between the two groups. For the 35 patients enrolled in the FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable between the two arms. A shorter viral clearance time was found for the FPV arm versus the control arm (median (interquartile range, IQR), 4 (2.5–9) d versus 11 (8–13) d, P < 0.001). The FPV arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.43% versus 62.22% (P = 0.004). After adjustment for potential confounders, the FPV arm also showed a significantly higher improvement rate in chest imaging. Multivariable Cox regression showed that FPV was independently associated with faster viral clearance. In addition, fewer adverse reactions were found in the FPV arm than in the control arm. In this open-label nonrandomized control study, FPV showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance; if causal, these results should be important information for establishing standard treatment guidelines to combat the SARS-CoV-2 infection.
has issue date	2020-03-18(xsd:dateTime)
bibo:doi	10.1016/j.eng.2020.03.007
bibo:pmid	32346491
has license	els-covid
sha1sum (hex)	995847926bde7c0022c3c2b8ac9f3f84756c221d
schema:url	https://doi.org/10.1016/j.eng.2020.03.007
resource representing a document's title	Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
has PubMed Central identifier	PMC7185795
has PubMed identifier	32346491
schema:publication	Engineering (Beijing)
resource representing a document's body	covid:995847926bde7c0022c3c2b8ac9f3f84756c221d#body_text
is schema:about of	named entity 'daily' named entity 'COVID-19' named entity 'combat' named entity 'Changes' named entity 'interquartile range' named entity 'chest' named entity 'viral' named entity 'IFN' named entity 'license' covid:arg/995847926bde7c0022c3c2b8ac9f3f84756c221d named entity 'control arm' named entity 'control arm' named entity 'addition' named entity 'ratio' named entity 'For' named entity 'clearance' named entity 'FPV' named entity 'effects' named entity 'received' named entity 'coronavirus disease 2019' named entity 'fatality' named entity 'December' named entity 'FPV' named entity 'COVID-19' named entity 'improvement' named entity 'compared' named entity 'arm' named entity 'FPV' named entity 'imaging' named entity 'infection' named entity 'patients' named entity 'Cox regression' named entity 'chest' named entity 'imaging' named entity 'faster' named entity 'Experimental' named entity 'chest imaging' named entity 'control arm' named entity 'interferon' named entity 'SARS-CoV-2' named entity 'control arm' named entity 'confounders' named entity 'Lopinavir' named entity 'aerosol' named entity 'chest imaging' named entity 'standard treatment' named entity 'acute respiratory distress syndrome' named entity 'Cox regression' named entity 'open-label' named entity 'China' named entity 'adverse reactions' named entity 'IFN-a' named entity 'COVID-19' named entity 'infection' named entity 'Lopinavir' named entity 'patients'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software